Research programme: unacylated ghrelin analogues - Alize Pharma
Alternative Names: AZP-01; AZP-01 programme; Non-acylated ghrelin; UAG; Unacylated ghrelinLatest Information Update: 02 Oct 2021
At a glance
- Originator Erasmus Medical Center; Theratechnologies; University of Torino
- Developer Alize Pharma
- Class Peptide hormones
- Mechanism of Action Ghrelin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 04 Dec 2014 No development reported - Preclinical for Type-2 diabetes mellitus in France (Parenteral)
- 04 Jun 2012 Alize Pharma and Eli Lilly complete their research collaboration for the UAG programme
- 13 Feb 2009 AZP 01 still in active development with Alizé Pharma for Type 1 and Type 2 diabetes mellitus in France